
BETHESDA, MD - November 18, 2026 - (KOREWIRE) - BioTech Social Inc. (BSI), parent company of BioTech Funding Portal, today announced that Karen Snow, former Global Head of Listings at Nasdaq, has joined its Advisory Board.
Snow brings more than 30 years of experience across investment banking, capital markets, corporate strategy, governance, sales, and company growth. Her addition brings deep public- and private-market expertise to BSI as the company pursues its broader strategy of building financial infrastructure around life science innovation.
BioTech Funding Portal, BSI’s SEC-registered and FINRA-member Regulation Crowdfunding portal, represents the company’s first implementation of that strategy. The portal enables eligible life science companies to raise up to $5 million annually from retail investors under Regulation Crowdfunding. Over time, BSI intends to explore additional financial structures, tools, and vehicles designed around the distinctive capital needs of life science companies.
“Life science companies face a financing journey unlike almost any other industry,” said Karen Snow. “They spend years advancing important science through research, clinical, and regulatory milestones before reaching traditional measures of commercial maturity. I’m excited to work with BioTech Social as it considers how new financing approaches can help promising companies access capital at different stages - ultimately positioning themselves for long-term success.”
Snow currently provides strategic counsel to companies across the private and public markets. Previously, she held a series of senior leadership roles at Credit Suisse and Nasdaq, culminating as Global Head of Listings, where she led the exchange’s global listings and capital markets business and advised public and private company executives and boards.
During her Nasdaq tenure, Snow led a business that oversaw more than 2,000 IPOs, supported more than 3,000 listed companies, and executed 185 exchange switches representing more than $1.5 trillion in market capitalization.
Before Nasdaq, Snow spent more than 18 years at Credit Suisse, where she held senior roles in investment banking and equities, including Managing Director and Head of New York Equity Sales. Earlier in her career, she worked in investment banking at Deutsche Bank. She holds an MBA from Georgetown University and a BS in Business from Babson College, where she currently serves on the Board of Trustees.
Building Financial Infrastructure Around the Science
BSI was formed around the premise that promising life science innovation can be constrained not only by translational uncertainty, but also by the availability and structure of capital.
That challenge is particularly evident in the life science “valley of death” - the period during which companies must continue funding research, clinical development, regulatory activities, and organizational growth, often before they generate meaningful commercial revenue or become candidates for traditional institutional financing.
“Karen understands the entire arc of company development and how capital needs change along the way,” said Dr. Neva West, CEO and Co-Founder of BSI. “What matters is creating more opportunities for promising research to move forward so that its clinical potential can be validated. That is especially important for patients and communities waiting for new approaches to diseases where the unmet needs remain significant. Karen brings a perspective that can help us determine how the financial side of that journey can better support clinical development.”
Snow’s addition expands a multidisciplinary BSI Advisory Board whose members bring experience across biotechnology, healthcare, finance, technology, patient advocacy, communications, company building, and capital formation.

About BioTech Social Inc.
BioTech Social Inc. is building financial infrastructure around life science innovation. The company develops platforms, tools and financial structures intended to expand access to capital for biotechnology, pharmaceutical, medical technology, diagnostic, digital health and other life science companies. BioTech Social Inc. is the parent company of BioTech Funding Portal LLC. www.biotech.social
About BioTech Funding Portal
BioTech Funding Portal is an SEC-registered funding portal and FINRA member focused exclusively on life science companies raising capital under Regulation Crowdfunding. The portal enables eligible companies to raise up to $5 million in capital annually from individual investors while providing a broader population of investors access to private life science investment opportunities under Regulation Crowdfunding.
Investment opportunities offered through BioTech Funding Portal are speculative, illiquid and involve a high degree of risk, including the possible loss of the entire investment. This press release is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy any security. Any securities offering conducted through BioTech Funding Portal is made only pursuant to applicable offering materials filed with the U.S. Securities and Exchange Commission. www.biotech.fund
Contact:
Lee-Ann Murphy
BioTech Social Inc
leeann@biotech.social